Lightbridge Q2 EPS $(0.27) Up From $(0.66) YoY
Lightbridge (NASDAQ:LTBR) reported quarterly losses of $(0.27) per share. This is a 59.09 percent increase over losses of $(0.66) per share from the same period last year.
Zynerba Pharmaceuticals Q2 EPS $(0.25) Misses $(0.24) Estimate
Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 67.95 percent increase over losses of $(0.78) per
Sutro Biopharma Q2 EPS $(0.13) Up From $(0.60) YoY, Sales $28.05M Up From $9.47M YoY
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.13) per share. This is a 78.33 percent increase over losses of $(0.60) per share from the same period last year. The company reported $28.05 million in
Tegna Provides Updated Q3 and 2021 Guidance
THIRD QUARTER AND FULL-YEAR 2021 OUTLOOK
In the third quarter of 2021, TEGNA expects strong subscription revenue and the continued recovery of advertising and marketing services revenue to offset the
Tegna Q2 EPS $0.50, Inline, Sales $732.91M Beat $732.37M Estimate
Tegna (NYSE:TGNA) reported quarterly earnings of $0.50 per share which met the analyst consensus estimate. This is a 316.67 percent increase over earnings of $0.12 per share from the same period last year. The company
Scientific Games Q2 Sales $880.00M Beat $765.23M Estimate
Scientific Games (NASDAQ:SGMS) reported quarterly sales of $880.00 million which beat the analyst consensus estimate of $765.23 million by 15.00 percent. This is a 63.27 percent increase over sales of $539.00 million
Kaleyra Affirms FY2021 Sales Guidance from $258.00M-262.00M to $258.00M-262.00M
Kaleyra (AMEX:KLR) affirms FY2021 sales outlook from $258.00 million-262.00 million to $258.00 million-262.00 million.
Kaleyra Sees Q3 Sales $79.500M-$80.500M vs $50.45M Est
Kaleyra (AMEX:KLR) sees Q3 sales of $79.500 million-80.500 million vs $50.45 million estimate.Kaleyra (AMEX:KLR) sees Q3 sales of $79.500 million-80.500 million vs $50.45 million estimate.
Kaleyra Q2 EPS $0.01 Beats $(0.17) Estimate, Sales $54.00M Beat $50.45M Estimate
Kaleyra (AMEX:KLR) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.17) by 105.88 percent. This is a 102.56 percent increase over losses of $(0.39) per share from the same
Immunovant Q1 EPS $(0.31) Misses $(0.30) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.30) by 3.33 percent. This is a 18.42 percent increase over losses of $(0.38) per share from the